GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

Japan’s MHLW accepts GSK’s regulatory application to expand use of RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease: London, UK Saturday, June ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Arexvy is currently approved for the prevention of lower respiratory tract disease (“LRTD”) caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged ...

(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...